



Published in final edited form as:

*Med Sci Sports Exerc.* 2018 October ; 50(10): 1992–1997. doi:10.1249/MSS.0000000000001658.

## Pulse Oximetry and Arterial Oxygen Saturation during Cardiopulmonary Exercise Testing

Mona Ascha<sup>1</sup>, Anirban Bhattacharyya<sup>2</sup>, Jose A Ramos<sup>2</sup>, and Adriano R Tonelli<sup>2</sup>

<sup>1</sup>Case Western Reserve University School of Medicine, Cleveland, OH

<sup>2</sup>Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH

### Abstract

**Introduction/Purpose**—Peripheral capillary oxygen saturation (SpO<sub>2</sub>) is used as surrogate for arterial blood oxygen saturation. We studied the degree of discrepancy between SpO<sub>2</sub> and arterial oxygen (SaO<sub>2</sub>) and identified parameters that may explain this difference.

**Methods**—We included patients who underwent cardiopulmonary exercise testing (CPET) at Cleveland Clinic. Pulse oximeters with forehead probes measured SpO<sub>2</sub> and arterial blood gas (ABG) samples provided the SaO<sub>2</sub> both at rest and peak exercise.

**Results**—We included 751 patients, 54 ± 16 years old with 53 % of female gender. Bland-Altman analysis revealed a bias of 3.8% with limits of agreement of 0.3 to 7.9% between SpO<sub>2</sub> and SaO<sub>2</sub> at rest. A total of 174 (23%) patients had SpO<sub>2</sub> >= 5% of SaO<sub>2</sub>, and these individuals were older, current smokers with lower FEV1 and higher PaCO<sub>2</sub> and carboxyhemoglobin. At peak exercise (n=631), 75 (12%) SpO<sub>2</sub> values were lower than the SaO<sub>2</sub> determinations reflecting difficulties in the SpO<sub>2</sub> measurement in some patients. The bias between SpO<sub>2</sub> and SaO<sub>2</sub> was 2.6% with limits of agreement between -2.9 to 8.1%. Values of SpO<sub>2</sub> >= 5% of SaO<sub>2</sub> (n=78, 12%) were associated with the significant resting variables plus lower heart rate, oxygen consumption

---

**Address for correspondence:** Adriano Tonelli MD, 9500 Euclid Avenue A-90, Cleveland, Ohio, 44195, Tel: +1 (216) 444-0812, Fax: +1 (216) 445-6024, tonella@ccf.org.

**Conflict of Interest Statements:**

**Mona Ascha BS:** The author has no significant conflicts of interest with any companies or organization whose products or services may be discussed in this article.

**Anirban Bhattacharyya MD:** The author has no significant conflicts of interest with any companies or organization whose products or services may be discussed in this article.

**Jose A Ramos RT:** The author has no significant conflicts of interest with any companies or organization whose products or services may be discussed in this article.

**Adriano R Tonelli MD, MSc:** The author has no significant conflicts of interest with any companies or organization whose products or services may be discussed in this article.

**Contributions of authors:**

**Mona Ascha BS:** Participated in writing and critical revision of the manuscript for important intellectual content and final approval of the manuscript submitted.

**Anirban Bhattacharyya MD:** Participated in writing, collection of data, statistical analysis, writing and critical revision of the manuscript for important intellectual content and final approval of the manuscript submitted.

**Jose A Ramos RT:** Participated in collection of data and critical revision of the manuscript for important intellectual content and final approval of the manuscript submitted.

**Adriano R. Tonelli MD, MSc:** Participated in the conception of the manuscript, collection of data, writing and critical revision of the manuscript for important intellectual content and final approval of the manuscript submitted. Dr Tonelli is the guarantor of the paper, taking responsibility for the integrity of the work as a whole, from inception to published article.

and oxygen pulse. In multivariate analyses, carboxyhemoglobin remained significantly associated with the difference between SpO<sub>2</sub> and SaO<sub>2</sub> both at rest and peak exercise.

**Conclusion**—In the present study, pulse oximetry commonly underestimated the SaO<sub>2</sub>. Increased carboxyhemoglobin levels are independently associated with the difference between SpO<sub>2</sub> and SaO<sub>2</sub>, a finding particularly relevant in smokers.

### Keywords

pulse oximetry; arterial blood gas; cardiopulmonary exercise test; forehead probe; arterial oxygenation

## Introduction

Peripheral capillary oxygen saturation (SpO<sub>2</sub>) is commonly measured by pulse oximetry, which provides an indirect measurement of arterial oxygenation (SaO<sub>2</sub>) based on the differential absorption of light by oxygenated and deoxygenated blood during pulsatile blood flow (1). Pulse oximetry offers a non-invasive and rapid determination of SaO<sub>2</sub>, particularly when the SaO<sub>2</sub> is above 75% (2). Arterial blood gas (ABG) analysis provides a direct measurement of the arterial partial pressure of oxygen (PaO<sub>2</sub>) and SaO<sub>2</sub> among other important parameters that are used to assess ventilation and acid base status. However, ABG analysis requires more time and expense as well as an arterial puncture (3). Thus, SpO<sub>2</sub> is routinely used as surrogate for SaO<sub>2</sub>.

Precision and accuracy of SpO<sub>2</sub> readings can be affected by technical problems inherent to the measuring device or inadequate interpretation of the data (4). Some sources of error can be modified (i.e. improper probe placement, motion artifact, nail polish, and stray light) while others cannot (i.e., presence of carboxyhemoglobin, methemoglobin, and skin pigmentation). In cases of poor perfusion, the accuracy of the reading can be optimized by changing the probe to a different location (e.g. finger, ear lobe or forehead), applying heat or a vasodilator cream, placing the hand below the level of the heart or trying a different sensor or pulse oximeter (5,6).

A good agreement between SpO<sub>2</sub> and the reference method of ABG analysis has been reported by some authors (7), while others reported an over- or underestimation of the SaO<sub>2</sub> (8,9,10). Some studies have pointed out that SpO<sub>2</sub> may not always be a reliable method to predict SaO<sub>2</sub> (11, 12). High venous pressure states can falsely lower SpO<sub>2</sub> values (3,13). Furthermore, decreased accuracy of SpO<sub>2</sub> has been described in hypoxemic (8), hemodynamically compromised (9,10), and critically ill (14) patients, in whom an accurate and reliable monitoring is of major importance. Increases in carboxyhemoglobin and on certain occasions methemoglobin can lead to falsely normal or high SpO<sub>2</sub> readings, despite a low SaO<sub>2</sub> (13). The source of error caused by these two dyshemoglobins can be mitigated by using co-oximetry, which requires an ABG.

Most studies investigating agreement between SpO<sub>2</sub> and SaO<sub>2</sub> have concentrated on critically ill inpatient populations (3,14), and studies in healthier, outpatient cohorts both at rest and during exercise are lacking. The purpose of our study is to examine the degree of

discrepancy between SpO<sub>2</sub> and SaO<sub>2</sub> both at rest and at maximum exercise and identify parameters that may explain this difference. We hypothesize that the discrepancy between SpO<sub>2</sub> and SaO<sub>2</sub> increases at maximal exercise and that several factors (particularly carboxyhemoglobin) can explain this difference. To test our hypothesis we retrospectively examined a cohort of patients undergoing cardiopulmonary exercise testing (CPET) at our institution, compared SpO<sub>2</sub> with SaO<sub>2</sub> both at baseline and at peak exercise during CPET, and tested whether variables collected during CPET can explain the differences between SpO<sub>2</sub> and SaO<sub>2</sub>.

## Methods

### Study Population

The study was approved by the Institutional Review Board of the Cleveland Clinic (IRB # 15-1288). Data from 751 patients referred for CPET at the Respiratory Institute of the Cleveland Clinic, from January 2010 to January 2015, were retrospectively analyzed. Informed consent was waived.

### Pulse Oximetry and Arterial Oxygenation Determinations

Our CPET protocol included the use of pulse oximeters (Nonin Avant 4000 system, Nonin, Plymouth, MI, USA) with forehead probes to measure SpO<sub>2</sub> both at baseline and during exercise. We routinely placed two pulse oximetry probes on the forehead to test accuracy and only recorded the most reliable determination based on the quality of the SpO<sub>2</sub> waveform. Forehead oximetry probes were held in place by an elastic band. Respiratory therapists recorded the SpO<sub>2</sub> measurement only when the waveform had a dicrotic notch and was synchronized with the heart rate observed in the electrocardiographic monitoring (15). SpO<sub>2</sub> at the time of ABG acquisition was recorded both at rest and peak exercise to avoid temporal variations. Measurements at rest were done in the sitting position after the patient relaxed for at least 10 minutes.

As part of our CPET protocol, SaO<sub>2</sub> levels were obtained from ABG samples taken from individual punctures of the radial artery (usually the left one) while patients sat on the bicycle. We did not place an arterial catheter. ABG determinations were performed with co-oximetry using the ABL800 FLEX Blood Gas Analyzer (Radiometer, Brønshøj, Denmark). ABG determinations were reported at 37 degree Celsius without correction by the core body temperature. Both SpO<sub>2</sub> and SaO<sub>2</sub> determinations were taken at rest (before exercise) and at maximum exercise (during the last 1-2 minute, just before stopping). Reasons for not been able to obtain an ABG at maximum exercise include: more than two unsuccessful attempts, transition into the recovery phase, and gasometric findings indicative of venous blood. In every patient, we recorded the amount of oxygen supplementation administered at the time of the measurements. If the patient required any degree of oxygen supplementation, either at rest or during activities, the CPET (including baseline and exercise determinations) was done with a fraction of inspired oxygen (FiO<sub>2</sub>) of 30% using a bag reservoir.

## Cardiopulmonary Exercise Testing (CPET) Protocol

CPET was ordered by pulmonary physicians based on established indications and done on an electrically braked cycle ergometer following recommendations by the American Thoracic Society and American College of Chest Physicians (16). Electrodes were placed on the skin to be able to obtain a 12-lead electrocardiogram. Blood pressure (BP) was recorded using a cuff placed on the arm opposite to the ABG site. An appropriate face mask (7450 SeriesV2 Mask, Hans Rudolph, Shawnee, KS, USA) size was selected and a good seal was verified. Measurements were obtained with the MedGraphics Ultima system (MGC Diagnostics, Saint Paul, MN, USA) following the manufacturer's recommendations. We used different maximal incremental exercise testing protocols based on the evaluation of each patient and with the intention of adjusting the exercise duration to approximately 8-12 minutes. Tests were terminated when the patient reached exhaustion (defined as 10/10 on the Borg scale or the inability to maintain pedal speed) or developed pronounced dizziness, leg, knee, chest or back pain (16).

For our study we recorded the following CPET variables: work rate, oxygen uptake ( $\text{VO}_2$ ), carbon dioxide output ( $\text{VCO}_2$ ), respiratory exchange ratio, anaerobic threshold, tidal volume, respiratory rate, minute ventilation ( $\text{V}_E$ ),  $\text{V}_E/\text{VCO}_2$ ,  $\text{V}_E/\text{VO}_2$ , breathing reserve, end-tidal  $\text{PCO}_2$ , heart rate, heart rate reserve, blood pressure, oxygen pulse, exercise duration and reasons for stopping the test. We also recorded  $\text{SpO}_2$  and  $\text{SaO}_2$  as well as other ABG results (partial pressure of oxygen in arterial blood ( $\text{PaO}_2$ ), alveolar-arterial difference for oxygen pressure,  $\text{PaCO}_2$ , pH, bicarbonate, lactate, hemoglobin and carboxyhemoglobin), maximum voluntary ventilation measured at baseline, and forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and FEV1/FVC (17) both at baseline and immediately after exercise.

### Other variables

We collected data on age, gender, height, weight, smoking status, type of CPET protocol (5 to 30 Watts per minute), and reasons for the test. Reasons for ordering CPET were clustered in four groups including a) unexplained dyspnea, b) pre-operative work-up for cardiovascular or lung surgeries, c) diagnose or evaluate treatment response in exercise induced asthma, and d) others. In addition, we reviewed the patient's medications, time and contents of the last meal.

### Statistical Analysis

Descriptive statistics (mean  $\pm$  SD, median (interquartile range (IQR) or n (%)) were used to summarize demographic and clinically relevant variables. Continuous variables were compared with t-test. Categorical variables were tested using chi-square or Fisher exact test, when appropriate. Univariate linear regression was used to examine whether certain variables of interest eloquent were associated with the difference between  $\text{SpO}_2$  and  $\text{SaO}_2$  both at rest and peak exertion. Multivariate analysis was subsequently performed to examine the association between variables that achieved a p value  $< 0.10$  in the univariate analysis. Variables in the models were tested for multicollinearity using variance inflation factors (VIF) and removing variables with a value larger than 4. Bland-Altman analysis was used to display the degree of bias and limits of agreement between  $\text{SpO}_2$  and  $\text{SaO}_2$  both at rest and

peak exertion, using SaO<sub>2</sub> as the gold standard in the x axis. We compared the patient characteristics at rest and during exercise between subjects that showed a difference between SpO<sub>2</sub> and SaO<sub>2</sub> < 5% or ≥ 5%. This prespecified but arbitrary cut-off was chosen to reflect an eloquent difference between measurements. Statistical significance was defined as a p-value less than 0.05. All analyses were performed using R: a Language and Environment for Statistical Computing (version 3.3.0).

## Results

### Patient Demographics

The mean age of the cohort (n=751) was 54.1 ± 16.1 years. A total of 355 (47%) patients were male. The majority of the tests were ordered for unexplained dyspnea (n=558 [74.3%]). Table 1 presents the baseline characteristics of the patients.

### Oximetry at baseline

Results of the ABG analysis, spirometry and CPET at baseline are shown in Table 2. The baseline SpO<sub>2</sub> was 98.2 ± 1.8 %. The test was done on room air in 735 (97.9%) patients and on gas with 30% FiO<sub>2</sub> in the rest (n=16, 2.1%). The SpO<sub>2</sub> in individuals on room air and FiO<sub>2</sub> 30% was 98.2 ± 1.8 and 98.3 ± 1.3%, respectively. Meanwhile, the SaO<sub>2</sub> was 94.4 ± 1.7 and 95.2 ± 1.3% for those breathing room air and FiO<sub>2</sub> of 30%, respectively. At rest, Bland-Altman analysis comparing SpO<sub>2</sub> with SaO<sub>2</sub> (gold standard) demonstrated a bias of 3.8% with limits of agreement of -0.3% to 7.9% (Figure 1, panel A). The vast majority (96.8%) of SpO<sub>2</sub> values were higher than the SaO<sub>2</sub> determinations and it appears that the lower the SaO<sub>2</sub> the more pronounced the gap with SpO<sub>2</sub> (Figure 1, panel A).

To better identify the characteristics associated with a larger difference between SpO<sub>2</sub> and SaO<sub>2</sub> at rest, we compared patients in whom the SpO<sub>2</sub> was ≥ 5% points higher than the SaO<sub>2</sub> (n=174, 23%) vs those with <5% points difference (n=577, 77%) (Table 3). We noted that when the difference between SpO<sub>2</sub> and SaO<sub>2</sub> was ≥ 5%, patients were older, with a higher proportion of current smokers, higher carboxyhemoglobin and PaCO<sub>2</sub> and lower FEV1, end-tidal CO<sub>2</sub> and hemoglobin (table 3).

In a multivariate analysis, we noted that the variables that were independently associated with the difference between SpO<sub>2</sub> and SaO<sub>2</sub> were current smoker status (β=1.92 for current vs never smokers and β=1.47 for current vs ex-smokers, p<0.001 for both), higher carboxyhemoglobin (per 1 % change, β=0.49, p<0.001), and lower PaO<sub>2</sub> (per 1 mmHg change, β=-0.125, p=0.02), FEV1 (per 1 L change, β=-1.15, p=0.01), maximal voluntary ventilation (per 1 L/min change, β=-0.009, p=0.02), and hemoglobin (per 1 g/dL change, β=-0.125, p=0.02). Similar results were noted when we excluded maximal voluntary ventilation (a variable with a VIF close to 4) from the model.

### Oximetry at peak exercise

In 120 patients (16%) ABG was obtained at baseline but could not be obtained at peak exercise, therefore, at total 631 (84%) patients had both ABG and SpO<sub>2</sub> at peak exercise. Seventy-eight (12.4%) patients had a SpO<sub>2</sub> ≥ 5% points than the SaO<sub>2</sub>. Bland-Altman

analysis showed a bias of 2.6% with limits of agreement of -2.9% and 8.1% (Figure 1 panel B). Interestingly, at peak exercise, several SpO<sub>2</sub> values (n= 75, 11.9%) were lower than the SaO<sub>2</sub> determinations. At peak exercise, a SpO<sub>2</sub>  $\geq$  5% point higher than the SaO<sub>2</sub> was associated with older age, lower height and weight, current smoker status, higher PaCO<sub>2</sub>, bicarbonate, and carboxyhemoglobin, lower hemoglobin, FVC, FEV1, maximum heart rate, oxygen consumption, and O<sub>2</sub> pulse (Table 4). In multivariate analysis, the variables independently associated with the difference between SpO<sub>2</sub> and SaO<sub>2</sub> at peak exercise were lower FVC (per 1 L change,  $\beta$ =-0.27, p=0.001) and carboxyhemoglobin (per 1 % change,  $\beta$ =0.78, p<0.001).

A decrease in SaO<sub>2</sub>  $\geq$  4% during exercise is commonly considered clinically significant (16). At total of 26 (4%) patients had a decrease in SaO<sub>2</sub>  $\geq$  4% at maximum exercise and of them 20 (77%) had a drop in SpO<sub>2</sub>  $\geq$  4%. A drop in SpO<sub>2</sub>  $\geq$  4% had false positive and negative rates of 10% and 1%, respectively, for detecting a decrease in SaO<sub>2</sub> of  $\geq$  4%.

## Discussion

The present study improves the understanding of the magnitude, direction and potential sources of error of pulse oximetry during exercise. It validates that carboxyhemoglobin is an important factor in explaining the difference between SpO<sub>2</sub> and SaO<sub>2</sub>, and supports obtaining ABG determinations in certain patients, particularly current smokers. In addition we noted that a small proportion of patients had a falsely low SpO<sub>2</sub> reading during exercise that if not confirmed by ABG may lead to unnecessary testing.

The importance of pulse oximetry as a rapid, non-invasive tool to assess oxygenation cannot be understated. However, this methodology is susceptible to measuring error due to a variety of conditions. In general, the margin of error of SpO<sub>2</sub> is within 2% to 3% of the SaO<sub>2</sub> (14, 18, 19). Taking advantage of the large number of data collected and investigations performed at the time of CPET in our institution, we sought to test the accuracy of SpO<sub>2</sub> to estimate SaO<sub>2</sub> both at rest and at peak exercise with a particular focus in identifying factors accounting for the discrepancy between measurements.

In our laboratory and using the equipment described, we found that the bias between SpO<sub>2</sub> and SaO<sub>2</sub> did not increase during exercise (3.8% at baseline and 2.6% during the exercise), with the majority of the SpO<sub>2</sub> determinations overestimating SaO<sub>2</sub>, particularly when the SaO<sub>2</sub> was below 90% or patients were current smokers. At peak exercise, the limit of agreement between SpO<sub>2</sub> and SaO<sub>2</sub> widened by one third from a gap of 8.25 to 10.99%, with more determinations in which SpO<sub>2</sub> was lower than SaO<sub>2</sub>, reflecting limitations in the accurate determination of SpO<sub>2</sub>, particularly during exercise. We identified several patient's characteristics associated with  $\geq$  5% points higher SpO<sub>2</sub> compared to SaO<sub>2</sub>, such as older age, current smoker status, lower FEV1, and higher PaCO<sub>2</sub> and carboxyhemoglobin. In addition, during peak exercise, patients with a larger gap between SpO<sub>2</sub> and SaO<sub>2</sub> had lower heart rate, lower oxygen consumption and oxygen, pulse.

A few studies that included a small number of healthy patients tested the validity of pulse oximetry during maximal exercise and noted an under- (26,27) or overestimation (28,29) of



the SaO<sub>2</sub>, with some suggesting a better precision when using a forehead sensor (26). To our knowledge, our study is the first to investigate the inconsistencies between SpO<sub>2</sub> measured with a forehead probe and SaO<sub>2</sub> in an outpatient cohort both at rest and peak exercise. The majority of our patients underwent CPET for unexplained dyspnea or as part of pre-operative work-up. Other studies have examined the discordance between SpO<sub>2</sub> and SaO<sub>2</sub>; however, these cohorts consisted of critically ill inpatients or patients who recently underwent surgery (3, 8, 14, 20, 21, 22). Similar to these other investigations we noted that the bias between SpO<sub>2</sub> and SaO<sub>2</sub> at rest was 3.8%.

Motion artifact is one of the major causes of inaccurate pulse oximetry readings. We used a forehead probe to reduce the possibility of motion artifact and errors caused as a result of gripping the bicycle handlebars (15). We paid particular attention to the quality of SpO<sub>2</sub> waveform and test its accuracy against a second forehead probe. An accurate determination of SpO<sub>2</sub> is critical, since desaturations during CPET can lead to further invasive testing and expense. Although at rest we noted that SpO<sub>2</sub> systematically overestimates SaO<sub>2</sub>, at peak exercise we observed that 10 (1.6%) patients had an SpO<sub>2</sub> below the SaO<sub>2</sub>, in a range that could be considered hypoxemia (SpO<sub>2</sub> < 90%). In addition, in 10% of the patients we noted a drop in SaO<sub>2</sub> ≥ 4% during maximal exercise, at odds with the corresponding changes in SaO<sub>2</sub>. These discrepancies could be related to forehead hypoperfusion, venous congestion with venous pulsations (30) or inaccuracies in the SpO<sub>2</sub> determination due to head motion during the activity. Given these findings and the additional information provided by the test, we recommend obtaining an ABG both at baseline and particularly at peak exercise during CPET (unless contraindicated) either using repeated punctures or an arterial line. ABG collection adds discomfort and an extra expense to patients. In addition, the ABG needs to be obtained at maximum exercise, since values can rapidly change in the recovery phase. Taking this caveats into consideration, we believe in confirming unexpected SpO<sub>2</sub> values with ABG analysis, particularly during exercise.

One of the main factors involved in the falsely high SpO<sub>2</sub> readings is carboxyhemoglobin (13), which absorbs light at approximately the same spectrum as oxyhemoglobin. Therefore, the determination presented by the pulse oximeter is a summation of oxyhemoglobin plus carboxyhemoglobin. This is particularly relevant in smokers, as noted in our analyses, and may explain the association with lower FEV1 and higher PaCO<sub>2</sub>. In our cohort, carboxyhemoglobin was an important factor, however, it explained less than half of the difference between SpO<sub>2</sub> and SaO<sub>2</sub>. Co-oximetry, which measures light absorbance at multiple wave lengths, is certainly needed if this source of error is suspected. In addition, data obtained at rest showed that PaO<sub>2</sub> and hemoglobin were inversely associated with the difference between SpO<sub>2</sub> and SaO<sub>2</sub>; variables that may impact the accuracy of the pulse oximetry.

Our study is not without limitations: a) in 120 (16%) patients we could not obtain peak exercise ABG, b) pulse oximetry results were obtained with a forehead probe to minimize motion artifact (23), it is unclear if our findings can be extrapolated to finger probes, c) SpO<sub>2</sub> readings may vary according to the model of pulse oximeter used (13, 15, 25), and d) race was not recorded.

## Conclusion

In the present study, pulse oximetry commonly underestimated the arterial oxygen saturation. Increased carboxyhemoglobin levels are major contributors to the difference between arterial and pulse oxygen saturation both at rest and peak exercise; a finding particularly relevant in smokers.

## Acknowledgments

The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation, and statement that results of the present study do not constitute endorsement by ACSM.


**Funding Sources:** A.R.T. is supported by NIH grant # R01HL130307.

## References

1. Kacmarek RK, Stoller JK, Heuer AJ. Egan's Fundamentals of Respiratory Care. 10th. Mosby; 2012. Analysis and Monitoring of Gas Exchange; 398
2. Chapman KR, Liu FLW, Watson RM, Rebuck AS. Range of accuracy of two wavelength oximetry. *Chest*. 1986; 89:540–542. [PubMed: 3956279]
3. Zeserson E, Goodgame B, Hess JD, et al. Correlation of Venous Blood Gas and Pulse Oximetry With Arterial Blood Gas in the Undifferentiated Critically Ill Patient. *J Intensive Care Med*. 2016 E-publication ahead of print.
4. Kacmarek RK, Stoller JK, Heuer AJ. Egan's Fundamentals of Respiratory Care. 10th. Mosby; 2012. Analysis and Monitoring of Gas Exchange; 408
5. Kacmarek RK, Stoller JK, Heuer AJ. Egan's Fundamentals of Respiratory Care. 10th. Mosby; 2012. Analysis and Monitoring of Gas Exchange; 408–409.
6. Moyle JT. Uses and abuses of pulse oximetry. *Arch Dis Child*. 1996; 74(1):77–80. [PubMed: 8660057]
7. Bierman MI, Stein KL, Snyder JV. Pulse oximetry in the postoperative care of cardiac surgical patients. A randomized controlled trial. *Chest*. 1992; 102(5):1367–70. [PubMed: 1424853]
8. Benson JP, Venkatesh B, Patla V. Misleading information from pulse oximetry and the usefulness of continuous blood gas monitoring in a post cardiac surgery patient. *Intensive Care Med*. 1995; 21(5): 437–9. [PubMed: 7665754]
9. Vicenzi MN, Gombotz H, Krenn H, Dorn C, Rehak P. Transesophageal versus surface pulse oximetry in intensive care unit patients. *Crit Care Med*. 2000; 28(7):2268–70. [PubMed: 10921551]
10. Ibáñez J, Velasco J, Raurich JM. The accuracy of the Biox 3700 pulse oximeter in patients receiving vasoactive therapy. *Intensive Care Med*. 1991; 17(8):484–6. [PubMed: 1797894]
11. Jubran A, Tobin MJ. Reliability of pulse oximetry in titrating supplemental oxygen therapy in ventilator-dependent patients. *Chest*. 1990; 97(6):1420–5. [PubMed: 2347228]
12. Carter BG, Carlin JB, Tibballs J, Mead H, Hochmann M, Osborne A. Accuracy of two pulse oximeters at low arterial hemoglobin-oxygen saturation. *Crit Care Med*. 1998; 26(6):1128–33. [PubMed: 9635666]
13. Schnapp LM, Cohen NH. Pulse oximetry uses and abuses. *Chest*. 1990; 98(5):1244–1250. [PubMed: 2225973]
14. Van de louw A, Cracco C, Cerf C, et al. Accuracy of pulse oximetry in the intensive care unit. *Intensive Care Med*. 2001; 27(10):1606–13. [PubMed: 11685301]
15. Yamaya Y, Bogaard HJ, Wagner PD, Niizeki K, Hopkins SR. Validity of pulse oximetry during maximal exercise in normoxia, hypoxia, and hyperoxia. *J Appl Physiol*. 2002; 92(2):162–168. [PubMed: 11744656]
16. American Thoracic Society.; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med*. 2003 Jan 15; 167(2):211–77. [PubMed: 12524257]



17. Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS Task Force. Standardisation of spirometry. *Eur Respir J*. 2005 Aug; 26(2):319–38. [PubMed: 16055882]
18. Wouters PF, Gehring H, Meyfroidt G, et al. Accuracy of pulse oximeters: the European multi-center trial. *Anesth Analg*. 2002; 94(1 Suppl):S13–6. [PubMed: 11900030]
19. Webb RK, Ralston AC, Runciman WB. Potential errors in pulse oximetry. II. Effects of changes in saturation and signal quality. *Anaesthesia*. 1991; 46(3):207–12. [PubMed: 2014899]
20. Shibata O, Kawata K, Miura K, Shibata S, Terao Y, Sumikawa K. Discrepancy between SpO<sub>2</sub> and SaO<sub>2</sub> in a patient with severe anemia. *J Anesth*. 2002; 16(3):258–60. [PubMed: 14517653]
21. Ahmed S, Siddiqui AK, Sison CP, Shahid RK, Mattana J. Hemoglobin oxygen saturation discrepancy using various methods in patients with sickle cell vaso-occlusive painful crisis. *Eur J Haematol*. 2005; 74(4):309–14. [PubMed: 15777343]
22. Stewart KG, Rowbottom SJ. Inaccuracy of pulse oximetry in patients with severe tricuspid regurgitation. *Anaesthesia*. 1991; 46(8):668–70. [PubMed: 1887977]
23. Tomlinson AR, Levine BD, Babb TG. Low Pulse Oximetry Reading: Time for Action or Reflection? *Chest*. 2017; 151(4):735–736. [PubMed: 28390625]
24. Schnapp LM, Cohen NH. Pulse oximetry. Uses and abuses. *Chest*. 1990; 98(5):1244–50. [PubMed: 2225973]
25. Thilo EH, Andersen D, Wasserstein ML, Schmidt J, Luckey D. Saturation by pulse oximetry: comparison of the results obtained by instruments of different brands. *J Pediatr*. 1993; 122(4):620–6. [PubMed: 7681875]
26. Yamaya Y, Bogaard HJ, Wagner PD, Niizeki K, Hopkins SR. Validity of pulse oximetry during maximal exercise in normoxia, hypoxia, and hyperoxia. *J Appl Physiol (1985)*. 2002; 92(1):162–168. [PubMed: 11744656]
27. Norton LH, Squires B, Craig NP, McLeay G, McGrath P, Norton KI. Accuracy of pulse oximetry during exercise stress testing. *Int J Sports Med*. 1992; 13(7):523–527. [PubMed: 1459747]
28. Wood RJ, Gore CJ, Hahn AG, et al. Accuracy of two pulse oximeters during maximal cycling exercise. *Aust J Sci Med Sport*. 1997; 29(2):47–50. [PubMed: 9242977]
29. Orenstein DM, Curtis SE, Nixon PA, Hartigan ER. Accuracy of three pulse oximeters during exercise and hypoxemia in patients with cystic fibrosis. *Chest*. 1993; 104(4):1187–1190. [PubMed: 8404189]
30. Sami HM, Kleinman BS, Lonchyna VA. Central venous pulsations associated with a falsely low oxygen saturation measured by pulse oximetry. *J Clin Monit*. 1991; 7(4):309–312. [PubMed: 1812874]



**Figure 1. Bland-Altman plots testing the differences between SpO<sub>2</sub> and SaO<sub>2</sub> at rest and peak exercise**

Plots show the mean difference and 95% confidence interval between SpO<sub>2</sub> and SaO<sub>2</sub>, labeled by smoking status (current smoker, ex-smoker and never smokers). **Panel A:** determinations at rest. **Panel B:** determinations at peak exercise.

**Table 1**

## Baseline Characteristics

Variable	Baseline determinations mean $\pm$ SD, n (%)
<b>n</b>	751
<b>Age (years)</b>	54 $\pm$ 16
<b>Male gender</b>	355 (47.3)
<b>Height (cm)</b>	172.0 $\pm$ 6.2
<b>Weight (kg)</b>	84.2 $\pm$ 21.6
<b>BMI (kg/m<sup>2</sup>)</b>	29.0 $\pm$ 7.0
<b>Smoking Status</b> *	
Current Smoker	68 (9.1%)
Ex-Smoker	307 (41.0)
Never Smoker	374 (49.9)
<b>Reason for CPET Testing</b> <sup>^</sup>	
Unexplained Dyspnea	558 (74.3)
Pre-Operative Workup	180 (24.0)
Exercise-Induced Asthma	3 (0.4)
Other	9 (1.2)

**Abbreviations:** BMI = body mass index; CPET = cardiopulmonary exercise testing; SD = standard deviation.

\* Smoking status is missing in 2 patients,

<sup>^</sup> reason for CPET testing is missing in 1 patient.

**Table 2**

CPET determinations at rest and peak exercise

Variable	Resting determinations mean $\pm$ SD, n (%)	Peak exercise determinations mean $\pm$ SD, n (%)
n	751	631
<i>ABG Parameters</i>		
pH	7.42 $\pm$ 0.03	7.35 $\pm$ 0.05
PaO <sub>2</sub> (mmHg)	87.8 $\pm$ 11.4	97.9 $\pm$ 16.9
PaCO <sub>2</sub> (mmHg)	37.7 $\pm$ 4.2	34.4 $\pm$ 5.9
HCO <sub>3</sub> (meq/L)	24.2 $\pm$ 2.2	18.7 $\pm$ 4.9
SaO <sub>2</sub> (%)	94.4 $\pm$ 1.7	94.5 $\pm$ 2.8
Hemoglobin (g/dL)	13.9 $\pm$ 2.0	15.0 $\pm$ 4.0
Carboxyhemoglobin (%)	1.49 $\pm$ 0.87	1.23 $\pm$ 0.77
A-a gradient (mmHg)	12.8 $\pm$ 11.4	19.5 $\pm$ 4.0
SpO <sub>2</sub> – SaO <sub>2</sub> (%)	3.82 $\pm$ 2.06	2.63 $\pm$ 2.75
<i>Spirometry Parameters</i>		
FEV1 (L)	2.6 $\pm$ 0.9	2.71 $\pm$ 1.05
FEV1 (% of predicted)	83.8 $\pm$ 20.2	
FEV1 % change		-1.9 $\pm$ 21.7
FVC (L)	3.4 $\pm$ 1.1	3.40 $\pm$ 1.31
FVC (% of predicted)	86.0 $\pm$ 17.9	
FVC % change		-2.2 $\pm$ 21.6
Minute ventilation (L/min)	11.8 $\pm$ 4.1	70.0 $\pm$ 25.0
<i>CPET Parameters</i>		
Heart rate (bpm)	82 $\pm$ 16	141 $\pm$ 26
Respiratory rate (rpm)	17 $\pm$ 5	42 $\pm$ 10
SpO <sub>2</sub> (%)	98.2 $\pm$ 1.8	97.1 $\pm$ 3.2
Oxygen consumption (ml/min)	319 $\pm$ 89	1760 $\pm$ 632
Oxygen consumption/kg (ml/min/kg)	3.9 $\pm$ 0.9	21.6 $\pm$ 8.8
Oxygen pulse (ml/min/bpm)	4.0 $\pm$ 1.2	12.5 $\pm$ 4.0
End tidal CO <sub>2</sub> (mmHg)	33.2 $\pm$ 5.0	34.3 $\pm$ 6.6

**Abbreviations:** ABG = arterial blood gas; BMI = body mass index; CO<sub>2</sub> = carbon dioxide; CPET = cardiopulmonary exercise testing; FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; HCO<sub>3</sub> = bicarbonate; O<sub>2</sub> = oxygen; PaO<sub>2</sub> = partial pressure of oxygen; PaCO<sub>2</sub> = partial pressure of carbon dioxide; SaO<sub>2</sub> = arterial hemoglobin oxygen saturation; SpO<sub>2</sub> = pulse oximetry; SD = standard deviation. FEV1 and FVC % change refer to the percent variation post-exercise spirometry when compared to the resting determination.

**Table 3**Patient characteristics based on a difference between SpO<sub>2</sub> and SaO<sub>2</sub> < 5% or ≥ 5% at rest.

Variables	SpO <sub>2</sub> – SaO <sub>2</sub> <5% mean ± SD, n (%)	SpO <sub>2</sub> – SaO <sub>2</sub> ≥5% mean ± SD, n (%)	P-value (t-test, chi-square)
n (%)	577 (76.8)	174 (23.2)	
Age (years)	53 ±17	59 ±13	<0.001
Male gender	271 (47.0)	84 (48.3)	0.84
Height (cm)	170.3 ±10.0	168.2 ±10.5	0.01
Weight (kg)	84.6 ±21.4	82.7 ±22.3	0.30
BMI (kg/m <sup>2</sup> )	29 ±7.0	29 ±6.8	0.88
<b>Smoking status</b>			
Current smoker	20 (3.5)	48 (27.6)	<0.001
Ex-smoker	236 (41.0)	71 (40.8)	
Never smoker	319 (55)	55 (31.6)	
<b>Reason for CPET testing</b>			
Unexplained dyspnea	447 (77.6)	111 (63.4)	<0.001
Pre-operative workup	118 (20.5)	62 (35.4)	
Exercise induced asthma	3 (0.5)	0 (0)	
Other	7 (1.2)	2 (1.1)	
<b>FiO<sub>2</sub> (%)</b>			
21%	563 (97.6)	172 (98.8)	0.48
30 %	14 (2.4)	2 (1.2)	
<b>ABG Parameters</b>			
pH	7.43 ±0.03	7.42 ±0.03	0.018
PaO <sub>2</sub> (mmHg)	90.0 ±10.9	80.6 ±10.1	<0.001
PaCO <sub>2</sub> (mmHg)	37.5 ±4.3	38.4 ±3.8	0.011
HCO <sub>3</sub> (mEq/L)	24.1 ±2.2	24.3 ±1.9	0.29
SaO <sub>2</sub> (%)	94.9 ±1.3	92.7 ±1.8	<0.001
Hemoglobin (g/dL)	14.0 ±2.0	13.5 ±2.0	0.014
Carboxyhemoglobin (%)	1.31 ±0.46	2.07 ±1.50	<0.001
A-a gradient (mmHg)	11.2 ±10.6	18.0 ±12.4	<0.001
<b>Spirometry Parameters</b>			
FEV1 (L)	2.7 ±0.9	2.3 ±0.9	<0.001
FEV1 (% of predicted)	85.4 ±19.5	78.7 ±21.6	<0.001
FVC (L)	3.5 ±1.1	3.26 ±1.1	0.01
FVC (% of predicted)	86.3 ±17.8	84.7 ±18.5	0.27
Minute Ventilation (l/min)	12.0 ±4.4	12.0 ±3.2	0.7
<b>CPET Parameters</b>			
Heart Rate (bpm)	82 ±16	83 ±15	0.57

Variables	SpO <sub>2</sub> – SaO <sub>2</sub> <5% mean ± SD, n (%)	SpO <sub>2</sub> – SaO <sub>2</sub> ≥5% mean ± SD, n (%)	P-value (t-test, chi-square)
Respiratory rate (rpm)	17 ±5.2	18 ±4.5	0.11
SpO <sub>2</sub> (%)	97.9 ±1.9	99.1 ±1.1	<0.001
Oxygen consumption (ml/min)	321 ±91	312 ±84	0.24
Oxygen consumption/Kg (ml/min/kg)	3.9 ±0.9	3.9 ±0.9	0.91
Oxygen pulse (ml/min/bpm)	4.0 ±1.3	3.9 ±1.1	0.11
End-tidal CO <sub>2</sub> (mmHg)	33.4 ±4.9	32.4 ±5.3	0.018

**Abbreviations:** = Difference between, ABG = arterial blood gas; BMI = body mass index; CO<sub>2</sub> = carbon dioxide; CPET = cardiopulmonary exercise testing; FEV1 = forced expiratory volume in one second; FiO<sub>2</sub>= inspired fraction of oxygen; FVC = forced vital capacity; HCO<sub>3</sub> = bicarbonate; O<sub>2</sub> = oxygen; PaO<sub>2</sub> = partial pressure of oxygen; PaCO<sub>2</sub> = partial pressure of carbon dioxide; SaO<sub>2</sub> = arterial hemoglobin oxygen saturation; SpO<sub>2</sub> = pulse oximetry; SD = standard deviation



**Table 4**Patient characteristics based on a difference between SpO<sub>2</sub> and SaO<sub>2</sub> < 5% or ≥ 5% at peak exercise.

Variables	SpO <sub>2</sub> – SaO <sub>2</sub> <5% mean ± SD, n (%)	SpO <sub>2</sub> – SaO <sub>2</sub> ≥5% mean ± SD, n (%)	P-value (t-test, chi-square)
n (%)	553 (87.6)	78 (12.4)	
Age (years)	54 ±16	61 ±14	0.001
Male gender	276 (49.9)	32 (41.0)	0.178
Height (cm)	170.7 ±10.0	166.1 ±9.3	<0.001
Weight (kg)	85.9 ±21.4	79.0 ±21.3	0.007
BMI (kg/m <sup>2</sup> )	29.4 ±6.8	28.5 ±7.0	0.12
<b>Smoking status</b>			
Current smoker (%)	29 (5.3)	21 (26.9)	<0.001
Ex-smoker (%)	235 (42.6)	39 (50.0)	
Never smoker (%)	299 (52.2)	18 (23.1)	
<b>Reason for CPET testing</b>			
Unexplained dyspnea	424 (78.2)	49 (55.1)	1.00
Pre-operative workup	110 (20.3)	38 (42.7)	
Exercise induced asthma	2 (0.4)	0 (0)	
Other	5 (0.9)	2 (2.2)	
<b>FiO<sub>2</sub> (%)</b>			
21%	542 (98.0)	76 (97.4)	1.00
30%	11 (2.0)	2 (2.6)	
<b>ABG Parameters</b>			
pH	7.35 ±0.05	7.35 ±0.05	0.494
PaO <sub>2</sub> (mmHg)	100.2 ±15.9	81.8 ±15.0	<0.001
PaCO <sub>2</sub> (mmHg)	34.0 ±5.8	36.8 ±5.7	<0.001
HCO <sub>3</sub> (mEq/L)	18.5 (5.0)	20.0 ±3.3	0.011
SaO <sub>2</sub> (%)	94.9 (2.2)	91.4 ±4.0	<0.001
Hemoglobin (g/dL)	15.0 (4.3)	14.0 ±2.0	0.026
Carboxyhemoglobin (%)	1.14 ±0.59	1.85 ±1.37	<0.001
A-a gradient (mmHg)	17.8 ±13.2	32.0 ±13.7	<0.001
<b>Spirometry Parameters</b>			
FEV1 (L)	2.7 ±1.0	2.1 ±1.1	<0.001
FEV1(% change)	-1.1 ±19.8	-8.0 ±31.8	0.009
FVC (L)	3.5 ±1.3	2.8 ±1.4	0.002
FVC (% change)	-1.3 ±19.6	-8.6 ±31.7	0.005
Minute ventilation (l/min)	71.0 ±25.0	62.0 ±22.4	<0.001
<b>CPET Parameters</b>			
Heart rate (bpm)	142 ±26	132 ±24	<0.001

Variables	SpO <sub>2</sub> – SaO <sub>2</sub> <5% mean ± SD, n (%)	SpO <sub>2</sub> – SaO <sub>2</sub> >=5% mean ± SD, n (%)	P-value (t-test, chi-square)
Respiratory rate (rpm)	42 ±10	42 ±10	0.98
SpO <sub>2</sub> (%)	97.0 ±3.2	97.8 ±3.0	0.041
Oxygen consumption (ml/min)	1813 ±629	1387 ±519	<0.001
Oxygen consumption/kg (ml/min/kg)	22.0 ±9.0	18.2 ±7.0	<0.001
Oxygen pulse (ml/min/bpm)	12.8 ±4.0	10.6 ±3.4	<0.001
End-tidal CO <sub>2</sub> (mmHg)	32.5 ±5.3	32.0 ±4.7	0.639

**Abbreviations:** ABG = arterial blood gas; BMI = body mass index; CO<sub>2</sub> = carbon dioxide; CPET = cardiopulmonary exercise testing; FEV1 = forced expiratory volume in one second; FiO<sub>2</sub>= inspired fraction of oxygen; FVC = forced vital capacity; HCO<sub>3</sub> = bicarbonate; O<sub>2</sub> = oxygen; PaO<sub>2</sub> = partial pressure of oxygen; PaCO<sub>2</sub> = partial pressure of carbon dioxide; SaO<sub>2</sub> = arterial hemoglobin oxygen saturation; SpO<sub>2</sub> = pulse oximetry; SD = standard deviation

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript